Hodgkin lymphoma: A review and update on recent progress

S Shanbhag, RF Ambinder - CA: a cancer journal for clinicians, 2018 - Wiley Online Library
Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous
Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed …

The tumour microenvironment in B cell lymphomas

DW Scott, RD Gascoyne - Nature Reviews Cancer, 2014 - nature.com
B cell lymphomas are cancers that arise from cells that depend on numerous highly
orchestrated interactions with immune and stromal cells in the course of normal …

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

J Kline, J Godfrey, SM Ansell - Blood, The Journal of the …, 2020 - ashpublications.org
The clinical development of effective cancer immunotherapies, along with advances in
genomic analysis, has led to the identification of tumor environmental features that predict …

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

MR Green, S Rodig, P Juszczynski, J Ouyang… - Clinical cancer …, 2012 - AACR
Purpose: Programmed cell death ligand 1 (PD-L1) is a molecule expressed on antigen-
presenting cells that engages the PD-1 receptor on T cells and inhibits T-cell receptor …

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label …

CS Diefenbach, F Hong, RF Ambinder… - The Lancet …, 2020 - thelancet.com
Background Recognising that the immune suppressive microenvironment promotes tumour
growth in Hodgkin lymphoma, we hypothesised that activating immunity might augment the …

Hodgkin lymphoma

JM Connors, W Cozen, C Steidl, A Carbone… - Nature Reviews …, 2020 - nature.com
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and
numerous immune effector cells in the tumour microenvironment. The incidence of HL is …

Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells

M Ruella, M Klichinsky, SS Kenderian, O Shestova… - Cancer discovery, 2017 - AACR
Patients with otherwise treatment-resistant Hodgkin lymphoma could benefit from chimeric
antigen receptor T-cell (CART) therapy. However, Hodgkin lymphoma lacks CD19 and …

Hodgkin's lymphoma in adults

W Townsend, D Linch - The Lancet, 2012 - thelancet.com
Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with
favourable-risk, early-stage disease are excellent, and serial reductions in intensity of …

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

KL Tan, DW Scott, F Hong, BS Kahl… - Blood, The Journal …, 2012 - ashpublications.org
Increased tumor-associated macrophages (TAMs) are reported to be associated with poor
prognosis in classic Hodgkin lymphoma (CHL). We investigated the prognostic significance …

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

AJ Moskowitz, H Schöder, S Gavane… - Blood, The Journal …, 2017 - ashpublications.org
Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma
(HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study …